# Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

> **NCT04858256** · PHASE2 · RECRUITING · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 100 (estimated)

## Conditions studied

- T-Cell Neoplasm
- Lymphoproliferative Disorders

## Interventions

- **DRUG:** Pacritinib

## Key facts

- **NCT ID:** NCT04858256
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-29
- **Primary completion:** 2027-11
- **Final completion:** 2028-11
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04858256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04858256, "Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04858256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*